Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.

Sorry, there's nothing here.

Cite this paper

@article{Butterbaugh2017TrastuzumabUI, title={Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.}, author={S T Butterbaugh and Ramila Patel and Edward H. Romond and Aju Mathew}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2017} }